Eurand is a global specialty pharmaceutical company that develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had 6 partnered or proprietary products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and collaboration partners.
Eurand has a strong track record of developing products using its innovative drug formulation technologies. With integrated manufacturing and R&D facilities in the U.S. and Europe, the company has one of the broadest ranges of drug delivery platforms in the industry, including:
-Customized Drug Release
-Bioavailability Enhancement
-Taste Masking / Orally Disintegrating Tablets (ODTs)
These platforms include 8 distinct technologies and are covered by more than 600 granted and pending patents. Eurand uses these technologies to develop and expand the Company's own internal pipeline and to partner with pharmaceutical and biopharmaceutical companies to develop their products.
Currently more than 40 products using these technologies are commercialized worldwide in a range of therapeutic indications.
Eurand is a leading industry partner that provides the broadest range of novel and proven oral drug delivery technologies. Using these technologies, we turn difficult drug candidates into easy-to-administer, successful pharmaceutical products. Additionally, our technologies can be used to enable the creation of new chemical entities and can also be used as innovative and effective life cycle management tools that can prolong the market life of products.
We have a number of Rx and OTC products available for licensing. In general, these products are new formulations of existing drugs that incorporate one or more of our proprietary drug delivery technologies. We license these products to pharmaceutical companies for marketing throughout the world.
We manufacture all of the products that we develop for ourselves and our licencees. Our manufacturing processes and units are integrated with our R&D facilities thereby facilitating the scale-up and manufacturing process for products in development. Shared facilities, processes, and development teams enhance this strategy. Additionally, we have facilities in the U.S. and in Italy approved to process controlled substances. Our manufacturing sites are regularly inspected by national regulatory agencies and our licencees.
